)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Elutia
Elutia (ELUT) investor relations material
Elutia Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary5 Nov, 2026
Executive summary
NXT-41x’s GLP rabbit study met prespecified endpoints; FDA submission is planned for Q4 2026, with clearance expected in 2027 and launch planned for 2H 2027–2028.
$26M in financing and asset-sale proceeds was secured without an equity offering; management expects available capital to support development through anticipated clearance and the first full commercial year.
Continuing-operations sales grew 20.4% YoY, while higher NXT-41/NXT-41x R&D widened the continuing-operations loss.
Following divestitures, the portfolio is focused on cardiovascular products and development of NXT-41 and antibiotic-eluting NXT-41x.
Financial highlights
Q3 continuing-operations net sales were $1.137M vs. $0.944M; nine-month sales were $3.306M vs. $2.007M.
Q3 operating loss was $6.896M vs. $5.869M; continuing-operations net loss was $6.503M vs. $1.044M.
Q3 net loss was $1.285M vs. $3.868M, including $5.218M income from discontinued operations.
Q3 adjusted EBITDA loss was $5.551M vs. $3.403M; nine-month adjusted EBITDA loss was $15.194M vs. $10.521M.
Cash and cash equivalents were $29.1M at September 30, 2026.
Outlook and guidance
NXT-41x FDA submission is planned for Q4 2026; clearance is anticipated in 2027, with a soft launch in 2H 2027 and full commercial launch in 2028, subject to FDA review.
NXT-41, on a separate pathway and not intended for commercialization, was expected to receive an FDA clearance decision in Q4 2026.
Automated coating capacity is designed to support at least $300M in revenue and gross margin above 80% at scale.
Management expects existing cash to fund operating expenses and capital needs for at least one year after issuance; operating losses and negative operating cash flow are expected to continue.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Elutia
- Drug-eluting biomatrix targets surgical infections, with FDA clearance and launch set for 2027–2028.ELUT
H.C. Wainwright 28th Annual Global Investment Conference - Up to $26M in funding secured, improved margins, and strong surgeon demand for NXT-41x.ELUTQ2 2026
- New drug-eluting biologic envelope gains traction with major partner and strong clinical benefits.ELUTPlanet MicroCap Showcase: VEGAS 2025
- EluPro's rapid adoption and a robust pipeline position the company for significant growth.ELUTCantor Global Healthcare Conference 2025
- Drug-eluting mesh targets high breast reconstruction infection rates, with launch expected next year.ELUTPlanet MicroCap Las Vegas 2026
- Antibiotic-eluting matrix targets high breast reconstruction infection rates in a $1.5B market.ELUT16th Annual LD Micro Invitational Conference
- Net sales up 6%, gross margin improved, and NXT-41/41x on track for 2026–2027 launch.ELUTQ1 2026
- Votes will address director elections, auditor ratification, incentive plan, and executive pay.ELUTProxy filing
- FDA clearance for EluPro and improved margins offset by a $28.2M net loss and going concern risks.ELUTQ2 2024
Next Elutia earnings date
Q4 20265 Mar, 2027
Elutia
Next Elutia earnings date
Q4 20265 Mar, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Elutia Inc., formerly known as Aziyo Biologics, Inc., is a commercial-stage company that focuses on developing and commercializing drug-eluting biomatrix technology to improve surgical outcomes. This technology is applied in products such as the CanGaroo Envelope, which is used to stabilize implantable cardiac devices like pacemakers and defibrillators, and SimpliDerm Acellular Dermal Matrix, which is utilized primarily in breast reconstruction following mastectomy. Elutia's mission revolves around humanizing medicine to ensure patients can thrive without the compromise, addressing the challenges associated with medical device implant failures and post-surgical complications. By integrating drug-eluting biologic technology with natural biologic material and extended antibiotic release, Elutia aims to optimize device implantation and soft tissue reconstruction, ensuring implant stability and promoting wound healing. Elutia Inc. is headquartered in Silver Spring, Maryland, and its shares are listed on the NASDAQ.